Immunotherapy for Epstein-Barr Virus-Associated Malignancies

Heather Long, Gregory Parsonage, Christopher Fox, Steven Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)


Epstein-Barr virus (EBV) is present in the malignant cells of several human cancers including post-transplant lymphoproliferative disease (PTLD), Hodgkin's Lymphoma, nasopharyngeal carcinoma, natural killer/T lymphomas and Burkitt's lymphoma. Yet in > 90% of the world's adult population, who carry EBV as a lifelong asymptomatic infection, the oncogenic potential of this virus is controlled by a strong virus-specific T-cell response. Accordingly, EBV-associated malignancies represent good candidates for a T-cell-based therapy and provide an important model for developing such therapies for other human cancers. This review summarizes the impressive results seen with T-cell therapy for PTLD and discusses, in the light of recent technological advances, the prospects for developing more effective approaches for other EBV-associated cancers.
Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalDrug News & Perspectives
Issue number4
Publication statusPublished - 1 May 2010


Dive into the research topics of 'Immunotherapy for Epstein-Barr Virus-Associated Malignancies'. Together they form a unique fingerprint.

Cite this